X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (553) 553
index medicus (431) 431
middle aged (393) 393
aged (370) 370
oncology (360) 360
male (346) 346
female (343) 343
adult (340) 340
hematology (334) 334
aged, 80 and over (247) 247
article (221) 221
prognosis (206) 206
treatment outcome (201) 201
leukemia (177) 177
cancer (165) 165
myelodysplastic syndromes (155) 155
acute myeloid-leukemia (145) 145
adolescent (136) 136
myelodysplastic syndromes - drug therapy (122) 122
antineoplastic combined chemotherapy protocols - therapeutic use (121) 121
hematology, oncology and palliative medicine (114) 114
abridged index medicus (109) 109
acute myeloid leukemia (109) 109
leukemia, myeloid, acute - drug therapy (107) 107
therapy (105) 105
myelodysplastic syndrome (104) 104
care and treatment (103) 103
young adult (102) 102
antineoplastic agents - therapeutic use (96) 96
survival (96) 96
research (95) 95
chemotherapy (93) 93
hemic and lymphatic diseases (91) 91
survival analysis (87) 87
disease-free survival (84) 84
remission induction (81) 81
mutation (76) 76
risk factors (76) 76
chronic myelogenous leukemia (74) 74
survival rate (74) 74
myelodysplastic syndromes - genetics (73) 73
acute myelogenous leukemia (72) 72
dna methylation (72) 72
imatinib mesylate (72) 72
myelodysplastic syndromes - mortality (72) 72
azacitidine - analogs & derivatives (68) 68
decitabine (65) 65
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (63) 63
leukemia, myeloid, acute - genetics (63) 63
aml (60) 60
follow-up studies (60) 60
myelodysplastic syndromes - pathology (59) 59
analysis (58) 58
azacitidine (58) 58
azacitidine - therapeutic use (57) 57
benzamides (55) 55
drug administration schedule (55) 55
leukemia, myeloid, acute - mortality (52) 52
retrospective studies (52) 52
cytarabine - administration & dosage (51) 51
patients (51) 51
chronic myeloid leukemia (50) 50
cytarabine (50) 50
genetic aspects (50) 50
recurrence (50) 50
acute lymphoblastic-leukemia (46) 46
kaplan-meier estimate (46) 46
pyrimidines - therapeutic use (46) 46
antineoplastic combined chemotherapy protocols - adverse effects (45) 45
mutations (45) 45
myelodysplastic syndromes - diagnosis (45) 45
cytogenetics (44) 44
diagnosis (44) 44
myeloid leukemia (44) 44
philadelphia chromosome (44) 44
transplantation (44) 44
dose-response relationship, drug (43) 43
scoring system (43) 43
chronic myeloid-leukemia (42) 42
drug therapy (42) 42
mds (42) 42
imatinib (41) 41
piperazines - therapeutic use (41) 41
risk (41) 41
antimetabolites, antineoplastic - therapeutic use (40) 40
patient outcomes (40) 40
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (40) 40
stem cells (40) 40
antineoplastic agents - administration & dosage (38) 38
chronic myelomonocytic leukemia (38) 38
dasatinib (38) 38
myelodysplastic syndromes - therapy (38) 38
dosage and administration (37) 37
protein kinase inhibitors - therapeutic use (37) 37
antineoplastic agents - adverse effects (36) 36
azacitidine - administration & dosage (36) 36
classification (36) 36
leukemia, myeloid, acute - pathology (36) 36
combination (35) 35
disease progression (35) 35
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 244 - 13
Journal Article
Cancer Medicine, ISSN 2045-7634, 11/2019, Volume 8, Issue 15, pp. 6559 - 6565
Introduction Imatinib is standard therapy for patients with chronic myeloid leukemia (CML). In February 2016, a generic formulation entered the US market.... 
leukemia | imatinib | safety | bioequivalence | generic | Edema | Imatinib | Laboratories | Myeloid leukemia | Leukemia | Diarrhea | Fatigue | Nausea | Chronic myeloid leukemia | FDA approval | Patients | Studies | Drug dosages | Pharmaceuticals
Journal Article
10/2019
The present invention relates to methods for the treatment of Myelodysplastic Syndrome, in particular subjects who have been shown to be refractory or... 
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS | HYGIENE | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | MEDICAL OR VETERINARY SCIENCE | HUMAN NECESSITIES
Patent
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S341 - S341
Journal Article
The Lancet Haematology, ISSN 2352-3026, 09/2019, Volume 6, Issue 9, pp. e480 - e488
Outcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent... 
YOUNGER PATIENTS | STEM-CELLS | ADULTS | DAUNORUBICIN | TIM-3 | HEMATOLOGY | EXPRESSION | T-CELLS | INDUCTION TREATMENT
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.